Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

Stockhead’s Ashtyn Hiron sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner.

The clinical stage biopharmaceutical company makes drugs that are designed to treat cancer better with its lead asset, bisantrene (RC220) , currently in Phase II trials for Acute Myeloid Leukemia.

“We’re about to start a series of new trials towards the second half of 2024 for solid tumours so basically all other cancers,” Tillett says.

Stay up to date via Race's interactive investor hub, and make sure to submit any questions you have via the 'Ask a question button'.

What's in store for 2024: Race Oncology